Commercial-stage oncology company whose approved medicines include Revuforj (revumenib) for relapsed or refractory acute leukemia and Niktimvo (axatilimab) for chronic graft-versus-host disease.
Company Info
Sector:Oncology
Headquarters:Waltham, Massachusetts, United States
Syndax Pharmaceuticals is ending development of its drug Niktimvo in lung fibrosis after a mid-stage study failed to deliver, a setback for the company's effort to widen the therapy beyond its approved uses.